Which medication class is typically used for the long-term management of autoimmune disorders?

Monoclonal antibodies are designed to target specific components of the immune system, making them particularly effective in the long-term management of autoimmune disorders. These medications can interfere with the activity of immune cells or block the action of cytokines, which are proteins that contribute to inflammation and immune responses. By precisely targeting these pathways, monoclonal antibodies can help to reduce the symptoms of autoimmune diseases and limit the damage caused by an overactive immune system.

In contrast, other classes of medications, while useful in managing symptoms or acute flares of autoimmune conditions, are not typically used for long-term management. For instance, H2 receptor antagonists primarily address gastrointestinal issues, such as ulcers and acid reflux, rather than autoimmune conditions. Non-steroidal anti-inflammatories (NSAIDs) can relieve pain and inflammation but often lack the specificity needed for enduring management of the underlying immune dysregulation. Corticosteroids are effective in suppressing inflammation and modulating immune responses but can have significant long-term side effects, such as increased risk of infection and metabolic complications, making them less desirable for chronic management when other targeted therapies, like monoclonal antibodies, are available.